ATE391777T1 - Verwendung von prohibitin-rns in krebsbehandlung - Google Patents

Verwendung von prohibitin-rns in krebsbehandlung

Info

Publication number
ATE391777T1
ATE391777T1 AT99935916T AT99935916T ATE391777T1 AT E391777 T1 ATE391777 T1 AT E391777T1 AT 99935916 T AT99935916 T AT 99935916T AT 99935916 T AT99935916 T AT 99935916T AT E391777 T1 ATE391777 T1 AT E391777T1
Authority
AT
Austria
Prior art keywords
prohibitin
rna
utr
portions
tumors
Prior art date
Application number
AT99935916T
Other languages
English (en)
Inventor
Eldon Jupe
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Application granted granted Critical
Publication of ATE391777T1 publication Critical patent/ATE391777T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99935916T 1998-07-24 1999-07-24 Verwendung von prohibitin-rns in krebsbehandlung ATE391777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9397798P 1998-07-24 1998-07-24

Publications (1)

Publication Number Publication Date
ATE391777T1 true ATE391777T1 (de) 2008-04-15

Family

ID=22242037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99935916T ATE391777T1 (de) 1998-07-24 1999-07-24 Verwendung von prohibitin-rns in krebsbehandlung

Country Status (6)

Country Link
EP (1) EP1100892B1 (de)
JP (1) JP2002522014A (de)
AT (1) ATE391777T1 (de)
CA (1) CA2336595A1 (de)
DE (1) DE69938501D1 (de)
WO (1) WO2000005359A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545705A4 (de) 2000-11-16 2010-04-28 Microspherix Llc Flexibler und/oder elastischer brachytherapie-seed oder strang
EP1791957B1 (de) * 2004-09-23 2013-07-31 AEterna Zentaris GmbH Prohibitin als ziel für krebstherapie
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
WO2021058145A1 (en) * 2019-09-24 2021-04-01 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Phage t7 promoters for boosting in vitro transcription

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658792A (en) * 1990-11-14 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Antiproliferative protein
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US6355427B1 (en) * 1996-11-07 2002-03-12 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility

Also Published As

Publication number Publication date
DE69938501D1 (de) 2008-05-21
CA2336595A1 (en) 2000-02-03
WO2000005359A1 (en) 2000-02-03
EP1100892B1 (de) 2008-04-09
EP1100892A1 (de) 2001-05-23
JP2002522014A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
Gray et al. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice
NO20014058L (no) TRPM-2-antisense-terapi
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
EP1165594A4 (de) Antisens oligonucleotide-modulierung der stat3 expression
EP1325019A4 (de) Antisense-modulation der clusterinexpression
DE69736432D1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
WO2002036743A3 (en) Antisense modulation of calreticulin expression
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
BR0008788A (pt) Sequencias anti-sentido antitumor dirigidas contra componentes r1 e r2 de ribonucleotìdeo reductase
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
DE60027870D1 (de) Genetische manipulierte herpesviren zur behandlung von tumoren
JP2006503904A5 (de)
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
ATE406155T1 (de) Triptolid-prodrugs zur krebstherapie
EP1004319A4 (de) Medikamente für massive tumore, welche inhibitoren der expression des wilms' tumorgens enthalten
EP1190040A4 (de) Herpes-simplex virus, das fremde gene exprimiert, und ein verfahren, um damit krebs zu behandeln
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
FI20010620A0 (fi) Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties